Toxicity and side effects of hydroxyurea used for primary thrombocythemia

References

• Yabro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992;19:1–10.
   Google Scholar
• Kennedy BJ. Hydroxyurea therapy in chronic myelogenous leukaemia. Cancer 1972;29:1052–1056.
   PubMed Web of Science ®Google Scholar
• Canstamzi YY, Vaitkevicius VR, Quagliama JM, et al. Combination chemotherapy for disseminated malignant melanoma. Cancer 1992;7:251–255.
   Google Scholar
• Dahl MGC, Camaish JS. Long-term effect of hydroxyurea in psoriasis. Br Med J 1972;4:585–587.
   PubMedGoogle Scholar
• Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risk and benefits up to 9 years of treatment. J Am Med Assoc 2003;289:1645–1651.
   PubMed Web of Science ®Google Scholar
• Frutchman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17–23.
   Google Scholar
• Tatarsky I, Sharon R. Management of polycythemia vera with hydroxyurea. Semin Hematol 1997;34:24–28.
   PubMed Web of Science ®Google Scholar
• Murphy S. Therapeutic dilemmas: balancing the risk of bleeding, thrombosis and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemost 1997;78:622–626.
   PubMed Web of Science ®Google Scholar
• Cortellazzo S, Finazzi G, Ruggeri M, Vetsri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New Engl J Med 1995;332:1132–1136.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Silverstein MN, Hoagland HC. Primary thrombo- cythemia. Semin Oncol 1995;22:334–340.
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain JD. Treatment of polycythemia: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90:3370–3377.
   PubMed Web of Science ®Google Scholar
• Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea treatment in polycythemia vera and allied disorders: prospective study of efficacy and leukemogenicity with therapeutic implications. Eur J Haematol 1994;52:134–139.
   PubMed Web of Science ®Google Scholar
• Kaplan ME, Mack K, Goldberg JD, et al. Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol 1986;23:167–171.
   PubMed Web of Science ®Google Scholar
• Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339–351.
   PubMed Web of Science ®Google Scholar
• Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombcythemia: an interim report from the polycythemia vera study group. Semin Hematol 1986;23:177–182.
   Google Scholar
• Wasserman LR, Balcerzak SP, Berk PD, et al. Influence of therapy on causes of death in polycythemia vera. Trans Assoc Am Physicians 1981;94:30–38.
   PubMedGoogle Scholar
• Lofvenberg E, Wahlin A. Management of polycythemia vera, essential thrombocythemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988;41:375–381.
   PubMed Web of Science ®Google Scholar
• Braester A, Quitt M. Hydroxyurea as a cause of drug fever. Acta Haematol 2000;104:50–51.
   PubMedGoogle Scholar
• Lannemyr O, Kutti J. Hydroxyurea as a cause of drug fever in essential thrombocythemia. Eur J Haematol 1999;62:354–355.
   PubMedGoogle Scholar
• in’t Veld BA, Slappendel AM, Feenstra J, Veem C, van Aken J, Runhaar EA, Stricker BHCH. Fever attributed to the use of hydroxyurea. Neth J Med 1997; 51:110–113.
   PubMedGoogle Scholar
• van der Klooster JM, Sucec PM, Stiegelis WF, Hagenbeek A. Fever caused by hydroxyurea: a report of three cases and review of the literature. Neth J Med 1997;51:114–118.
   Google Scholar
• Starmans-Kool MJF, Fickers MMF, Pannebakker MAG. An unwanted effect of hydroxyurea in a patients with idiopathic myelofibrosis. Ann Hematol 1995;70:279–280.
   PubMedGoogle Scholar
• Gallant C, Vial T, Allochon Y, Monier JM, Blanc M, Evreux JC. Fievre medicamenteuse induite par l’ hydroxyuree. Ann Med Interne 1998;149:9–61.
   Google Scholar
• Heddle R, Calvert AF. Hydroxyurea induced hepatitis. Med J Aust 1908;1:121.
   Google Scholar
• Kavuru MS, Gadsden T, Lichtin A, Gephardt G. Hydroxyurea-induced acute interstitial lung disease. South Med J 1994;87:767–768.
   PubMedGoogle Scholar
• Young HS, Khan ASA, Kendra JR, Coulson IH. The cutaneous side-effects of hydroxyurea. Clin Lab Haematol 2000;22:229–232.
   PubMedGoogle Scholar
• Vomvouras S, Pakula AS, Shaw JM. Multiple pigmented nail bands during hydroxyurea therapy: an uncommon finding. J Am Acad Dermatol 1991;24:1016–1017.
   PubMedGoogle Scholar
• Montefusco E, Alimena G, Gastaldi R, Carlesimo OA, Valesini G, Mandelli F. Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia. Tumori 1986;72:317–321.
   PubMedGoogle Scholar
• Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea- induced leg ulceration in 14 patients. Ann Int Med 1998;128:29–32.
   PubMed Web of Science ®Google Scholar
• Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am J Hematol 1996; 52:46–.Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, Bordessoule D, Bauters F, Fenaux P. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616–622.
   Google Scholar
• Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythemia treated with busulfan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577–583.
   PubMed Web of Science ®Google Scholar
• Murphy S, Peterson, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythe- mia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 1997;34:29–39.
   Google Scholar
• Randi ML, Fabris F, Girolami A. Leukemia and myelo- dysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leuk Lymph 2000;37:379–385.
   PubMed Web of Science ®Google Scholar